BRIEF-AstraZeneca Says Enhertu Granted Priority Review In US For Patients With HER2-Low Metastatic Breast Cancer

AstraZeneca PLC:

* ASTRAZENECA PLC - ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC

* ASTRAZENECA - ENHERTU GRANTED PRIORITY REVIEW IN US FOR PATIENTS WITH HER2-LOW METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)